Triple autoantibody-negative systemic sclerosis marks a distinct clinical subset in the SPRING registry
Among patients with systemic sclerosis, antibody status does more than satisfy classification criteria. It tracks with organ pattern, vascular burden, and the kind of bedside problems that shape long-term management. In the multicentric SPRING registry from the Italian Society for Rheumatology, nearly one in five patients fell into a triple autoantibody-negative category, lacking antitopoisomerase I, anticentromere, and anti-RNA polymerase III antibodies. That proportion is large enough to matter in routine rheumatology practice, especially because these antibodies are usually treated as the serologic anchors of disease subtyping.
The registry analysis evaluated 1,480 patients with systemic sclerosis and identified 295 triple-negative patients, representing 19.9% of the cohort. The remaining 1,185 patients carried one of the disease-specific antibodies, with anticentromere antibody positivity in 54.3%, antitopoisomerase I in 43.6%, and anti-RNA polymerase III in 2.1%. This distribution reinforces how dominant the standard serologic triad remains in systemic sclerosis, while also leaving a substantial minority of patients outside the classic antibody framework.
The signal that stands out most sharply is muscular involvement.
Triple-negative patients showed myopathy more often than antibody-positive patients, 16.7% versus 10.1%, with a p value of 0.003. Biochemically, that pattern was mirrored by higher creatine phosphokinase levels, 126.2 versus 92.5 U/mL, p=0.002, and by a greater frequency of marked CPK elevation above two to three times the upper limit of normal, 2.4% versus 0.2%, p=0.028. In clinical terms, this points toward a subgroup in which muscle injury or inflammatory myopathic features may be more prominent than the vasculopathic phenotype often emphasized in systemic sclerosis.
The vascular phenotype moved in the opposite direction. Patients without the three canonical antibodies had fewer digital ulcers, 17.3% versus 22.8%, p=0.04, and less calcinosis, 8.2% versus 12.8%, p=0.027. In a disease where microvascular injury drives pain, ischemia, ulceration, and disability, lower rates of these complications suggest that triple negativity may signal a different pathogenic mix rather than simply a milder version of the same condition. Endothelial dysfunction still belongs in systemic sclerosis, but the balance between vascular injury and other tissue compartments may shift when the standard autoantibody profile is absent.
Interstitial lung disease was also more prevalent in the triple-negative group, although the excerpted results end before the full comparison is completed. Even with that truncation, the direction of travel is clinically meaningful. Lung involvement and muscle disease in the same subset raise the possibility that these patients cluster around a broader fibrosing or overlap phenotype rather than the more classic antibody-linked subsets seen in day-to-day rheumatology clinics.
Serology in systemic sclerosis is often used as shorthand for prognosis, but the shortcut has limits. A patient can satisfy classification criteria and still fall outside the expected antibody map. In practice, that means a negative ATA, ACA, and RNAP3 panel should not reassure clinicians that the disease is biologically quiet; instead, it should prompt closer attention to nonvascular organ involvement, especially muscle and lung manifestations. The registry findings fit that concern. Triple negativity did not identify a benign subgroup. It identified a different one.
From a pathophysiologic standpoint, the pattern makes sense. Antibody-defined subsets of systemic sclerosis are often linked to recognizable clinical signatures: vascular complications, cutaneous phenotype, or specific internal organ risks. When those antibodies are absent, the disease may be driven by alternative immune pathways, with muscle inflammation or overlap features taking on a larger role. Elevated CPK and more frequent myopathy fit that framework. The lower rate of digital ulcers and calcinosis suggests that the vascular cascade, while still relevant, may not dominate the clinical picture to the same extent.
The registry design also matters. This was a retrospective evaluation within a multicenter cohort, which gives the findings breadth across real-world Italian rheumatology practice. At the same time, the design cannot prove causality, and the excerpt provided here does not supply granular data on disease duration, treatment exposure, cutaneous subset distribution, or pulmonary function. Those missing details limit mechanistic certainty, but they do not erase the core observation: a sizeable portion of patients with systemic sclerosis lack the three canonical disease-specific autoantibodies and show a recognizable enrichment of myopathic features.
For clinicians, the practical consequence is straightforward. Seronegativity for ATA, ACA, and RNAP3 should not be interpreted as an absence of systemic sclerosis biology. It should trigger a broader phenotyping mindset, with particular attention to muscle enzymes, weakness, and potential interstitial lung disease. In a field that often leans on serology to sort patients into prognostic buckets, this cohort argues for a more careful bedside read of the disease when those buckets come back empty.
The most important unanswered piece is how these triple-negative patients evolve over time, and whether their muscle- and lung-predominant profile translates into distinct long-term outcomes. The abstract excerpt stops before those endpoints are defined, leaving the natural history and treatment response of this subgroup unresolved.